TISSIUM Secures Up to €60M Financing to Accelerate Commercial Rollout of Sutureless Nerve Repair Platform
核心洞察
TISSIUM has secured a financing package worth up to €60 million ($68.2 million), including a €30 million Series D2 round and a €30 million facility from the European Investment Bank (搜索).
The funding will support the U.S. commercial rollout of Coaptium Connect (搜索), the company's first FDA-authorized sutureless platform for atraumatic peripheral nerve repair.
TISSIUM also appointed Marc Quartulli as Vice President of Clinical Affairs to strengthen clinical strategy and regulatory readiness across its three core indications.
TISSIUM, a medical technology company pioneering biomorphic programmable polymers for tissue reconstruction, has secured a financing package worth up to €60 million (approximately $68.2 million) to support the commercial rollout of its sutureless nerve repair platform. The package consists of a €30 million Series D2 financing completed in late 2025 and a facility of up to €30 million from the European Investment Bank (搜索) (EIB), the lending arm of the European Union.
The funding follows the company's receipt of de novo authorization from the U.S. Food and Drug Administration for the Coaptium Connect (搜索) sutureless platform in peripheral nerve repair. Coaptium Connect represents TISSIUM's first commercial product and leverages a bioresorbable light-activated surgical polymer combined with a 3D-printed polymer chamber to enable atraumatic, sutureless nerve repair.
"The investor and bank support reflects confidence in TISSIUM's technology and strategy," said Christophe Bancel, CEO and co-founder of TISSIUM.
The EIB facility is structured in three tranches of €10 million each, linked to commercial, clinical, and financing milestones. New and existing international investors, including those based in the U.S., participated in the Series D2 round.
Clinical Leadership Strengthened
In parallel with the financing, TISSIUM announced the appointment of Marc Quartulli as Vice President of Clinical Affairs. Quartulli brings extensive experience in clinical development and medical affairs across the medical device industry, most recently serving as Vice President of Clinical Affairs at AlvaMed, Inc. Prior to that, he held senior leadership roles at Conformis, including Vice President of Clinical Affairs, Professional Affairs & Market Access, where he led global clinical strategies for innovative orthopedic solutions.
Maria Pereira, Deputy CEO and Chief Innovation Officer of TISSIUM, stated: "Marc brings a strong track record in leading global clinical programs and translating innovative technologies into meaningful clinical outcomes. His expertise will be essential as we continue to expand our clinical footprint in our three indications (atraumatic peripheral nerve repair, atraumatic hernia repair, cardiovascular sealing) and accelerate the development of our platform to benefit patients worldwide."
Quartulli added: "I am excited to join TISSIUM at such a pivotal time in its development. The potential of its technology to address significant unmet needs in tissue reconstruction is highly compelling. I look forward to working closely with surgeons and clinical partners to advance robust clinical programs and help bring these innovations to patients."
Pipeline and Platform Expansion
Beyond nerve repair, TISSIUM is advancing applications in atraumatic hernia repair and cardiovascular sealing. The company received an investigational device exemption (IDE) from the FDA in September 2025 for a clinical trial to study its Eclipsium (搜索) treatment for ventral hernia (搜索) repair. The new funding will support clinical activities, expansion of the technology platform, and acceleration of the company's U.S. rollout.
TISSIUM's proprietary platform consists of fully biosynthetic, biomorphic, programmable, elastomeric polymers designed to address critical unmet needs in atraumatic tissue repair and reconstruction. Each solution is engineered to optimize tissue repair through controlled and consistent procedures, supported by specialized delivery and activation devices.
Founded in 2013, TISSIUM is built on breakthrough research and intellectual property originating from the laboratories of Professor Robert Langer at the Massachusetts Institute of Technology and Professor Jeffrey M. Karp at Brigham and Women's Hospital. The company maintains offices in Paris, France, and Cambridge, Massachusetts, with a manufacturing site in Roncq, France.